SuppreMol, Bayerische Patentallianz GmbH deal

SuppreMol licensed exclusive, worldwide rights from the University Hospital of Regensburg to preclinical compound SM401, a humanized mAb against IL-3 in preclinical development to diagnose and treat rheumatoid arthritis (RA). The company plans to begin clinical testing of SM401 in 2014. SuppreMol will also validate a diagnostic assay for IL-3 for patient stratification. Development of SM401 and the diagnostic have been funded by a €1.4 million ($1.7 million) grant from the German Federal Ministry of Education and Research (BMBF). Details were not disclosed. ...